These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2257872)

  • 41. Stereoselective effects of disopyramide enantiomers in humans.
    Lima JJ; Boudoulas H
    J Cardiovasc Pharmacol; 1987 May; 9(5):594-600. PubMed ID: 2439842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of the negative inotropic effect of disopyramide.
    Kenedi PP
    J Int Med Res; 1988; 16(4):257-63. PubMed ID: 3169371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt.
    Morillo CA; Leitch JW; Yee R; Klein GJ
    J Am Coll Cardiol; 1993 Dec; 22(7):1843-8. PubMed ID: 8245337
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Delayed-action disopyramide in the treatment of hyperkinetic ventricular arrhythmia. A randomized clinical comparative study vs immediate-action disopyramide].
    Romanò M; Spinelli A; Cazzani E; Muzio L
    Clin Ter; 1991 Jul; 138(1):13-9. PubMed ID: 1834395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concentration-response relationships of disopyramide in patients with ventricular tachycardia.
    Duff HJ; Mitchell LB; Nath CF; Manyari DE; Baynton R; Wyse DG
    Clin Pharmacol Ther; 1989 May; 45(5):542-7. PubMed ID: 2721110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maintenance therapy after i.v. administration of disopyramide with an oral sustained release preparation, a pharmacokinetic study.
    Liem KL; Hollander JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):226-8. PubMed ID: 6487461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The direct electrophysiologic effects of disopyramide phosphate in the transplanted human heart.
    Bexton RS; Hellestrand KJ; Cory-Pearce R; Spurrell RA; English TA; Camm AJ
    Circulation; 1983 Jan; 67(1):38-45. PubMed ID: 6401173
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers.
    Brion N; Beaumont D; Advenier C
    Br J Clin Pharmacol; 1988 Jan; 25(1):27-32. PubMed ID: 3130890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disopyramide plasma levels in cardiac patients on maintenance therapy.
    Landmark K; Storstein L; Larsen A
    Acta Med Scand; 1979; 206(5):385-9. PubMed ID: 525439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats.
    Karim A; Kook C; Campion J; Doherty M
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):222-36. PubMed ID: 921413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias.
    Arif M; Laidlaw JC; Oshrain C; Willis PW; Nissen CH; McDermott DJ; Smith WS; Karim A; Wilson RR
    Angiology; 1983 Jun; 34(6):393-400. PubMed ID: 6408949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of disopyramide on repolarisation and intraventricular conduction in man.
    Endresen K; Amlie JP; Forfang K
    Eur J Clin Pharmacol; 1988; 35(5):467-74. PubMed ID: 2466670
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
    Giacomini KM; Blaschke TF
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():42-8. PubMed ID: 6705426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
    Shaw LM; Doherty JU; Waxman HL; Josephson ME
    Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Maekawa C; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Nov; 23(11):1363-9. PubMed ID: 11085367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the effects of desipramine on noradrenaline- and methoxamine-evoked venoconstriction in man.
    Abdelmawla AH; Langley RW; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1995 Nov; 40(5):445-51. PubMed ID: 8703648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.
    Kerr CR; Prystowsky EN; Smith WM; Cook L; Gallagher JJ
    Circulation; 1982 May; 65(5):869-78. PubMed ID: 6804107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement of plasma disopyramide as a guide to paediatric use.
    Baker EJ; Hayler AM; Curry PV; Tynan M; Holt DW
    Int J Cardiol; 1986 Jan; 10(1):65-9. PubMed ID: 3943929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.